Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis

ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcome...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of affective disorders 2023-06, Vol.330, p.227-238
Hauptverfasser: de A. Simoes Moreira, Debora, Gauer, Luís Eduardo, Teixeira, Guilherme, Fonseca da Silva, Amanda Carolina, Cavalcanti, Stefanie, Quevedo, João
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 238
container_issue
container_start_page 227
container_title Journal of affective disorders
container_volume 330
creator de A. Simoes Moreira, Debora
Gauer, Luís Eduardo
Teixeira, Guilherme
Fonseca da Silva, Amanda Carolina
Cavalcanti, Stefanie
Quevedo, João
description ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220). We searched MEDLINE, Web of Science, Embase, PsycINFO, Google Scholar, Cochrane Library and trial registries, which were the ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform, without restrictions on publication date. Selection criteria: randomized controlled trials or cohorts comparing ketamine versus ECT in patients with TRD. Eight studies met the inclusion criteria (of 2875 retrieved). Random-effects models comparing ketamine and ECT regarding the following outcomes were conducted: a) reduction of depressive symptoms severity through scales, g = −0.12, p = 0.68; b) response to therapy, RR = 0.89, p = 0.51; c) reported side-effects: dissociative symptoms, RR = 5.41, p = 0.06; nausea, RR = 0.73, p = 0.47; muscle pain, RR = 0.25, p = 0.02; and headache, RR = 0.39, p = 0.08. Influential & subgroup analyses were performed. Methodological issues with high risk of bias in some of the source material, reduced number of eligible studies with high in-between heterogeneity and small sample sizes. Our study showed no evidence to support the superiority of ketamine over ECT for severity of depressive symptoms and response to therapy. Regarding side effects, there was a statistically significant decreased risk of muscle pain in patients treated with ketamine compared to ECT. •To our knowledge, this is the first meta-analysis comparing ketamine and ECT in the treatment of patients with TRD;•Our analysis showed no evidence to support the superiority of ketamine over ECT in reducing depression severity;•There is a lower risk of having muscle pain as a side effect when using ketamine compared with ECT for TRD.
doi_str_mv 10.1016/j.jad.2023.02.152
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2786511519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165032723003245</els_id><sourcerecordid>2786511519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-f6ac068f7421861442a16a3773e1c11b5085a83d3b630fb632d7303b0d62c3743</originalsourceid><addsrcrecordid>eNp9kc1u1DAUha2Kqp0WHoAN8pJNgn8SOwOrqioUqVI3sLY89rVwSOLBN5kqL8Ez4-kUlmyuF-e758rnEPKWs5ozrj70dW99LZiQNRM1b8UZ2fBWy0q0XL8im8K0FZNCX5IrxJ4xpraaXZBLqbZMN6rZkN93IURn3Urt5Kn1B8gIFEIANyNNgf6E2Y5xAnpUFqQwFCUnl6bDMmA8AJ1_QLb7lYaU6Wj7Mj3sM-Cz6COm7CF_pDcUV5xhtHN0NMMhwtPzzbEcqOxkhxUjvibnwQ4Ib17ea_L989232_vq4fHL19ubh8rJrZqroKxjqgu6EbxTvGmE5cpKrSVwx_muZV1rO-nlTkkWyhBeSyZ3zCvhpG7kNXl_8t3n9GsBnM0Y0cEw2AnSgkboTrWct3xbUH5CXU6IGYLZ5zjavBrOzLEG05tSgznWYJgwpYay8-7FftmN4P9t_M29AJ9OAJRPliiyQRdhcuBjLvkan-J_7P8AJaiaNg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2786511519</pqid></control><display><type>article</type><title>Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>de A. Simoes Moreira, Debora ; Gauer, Luís Eduardo ; Teixeira, Guilherme ; Fonseca da Silva, Amanda Carolina ; Cavalcanti, Stefanie ; Quevedo, João</creator><creatorcontrib>de A. Simoes Moreira, Debora ; Gauer, Luís Eduardo ; Teixeira, Guilherme ; Fonseca da Silva, Amanda Carolina ; Cavalcanti, Stefanie ; Quevedo, João</creatorcontrib><description>ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220). We searched MEDLINE, Web of Science, Embase, PsycINFO, Google Scholar, Cochrane Library and trial registries, which were the ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform, without restrictions on publication date. Selection criteria: randomized controlled trials or cohorts comparing ketamine versus ECT in patients with TRD. Eight studies met the inclusion criteria (of 2875 retrieved). Random-effects models comparing ketamine and ECT regarding the following outcomes were conducted: a) reduction of depressive symptoms severity through scales, g = −0.12, p = 0.68; b) response to therapy, RR = 0.89, p = 0.51; c) reported side-effects: dissociative symptoms, RR = 5.41, p = 0.06; nausea, RR = 0.73, p = 0.47; muscle pain, RR = 0.25, p = 0.02; and headache, RR = 0.39, p = 0.08. Influential &amp; subgroup analyses were performed. Methodological issues with high risk of bias in some of the source material, reduced number of eligible studies with high in-between heterogeneity and small sample sizes. Our study showed no evidence to support the superiority of ketamine over ECT for severity of depressive symptoms and response to therapy. Regarding side effects, there was a statistically significant decreased risk of muscle pain in patients treated with ketamine compared to ECT. •To our knowledge, this is the first meta-analysis comparing ketamine and ECT in the treatment of patients with TRD;•Our analysis showed no evidence to support the superiority of ketamine over ECT in reducing depression severity;•There is a lower risk of having muscle pain as a side effect when using ketamine compared with ECT for TRD.</description><identifier>ISSN: 0165-0327</identifier><identifier>ISSN: 1573-2517</identifier><identifier>EISSN: 1573-2517</identifier><identifier>DOI: 10.1016/j.jad.2023.02.152</identifier><identifier>PMID: 36907464</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antidepressive Agents - adverse effects ; Depressive Disorder, Major - drug therapy ; ECT ; Electroconvulsive Therapy - adverse effects ; Humans ; Ketamine ; Ketamine - adverse effects ; MDD ; Meta-analysis ; Mood disorders ; Myalgia - drug therapy ; TRD</subject><ispartof>Journal of affective disorders, 2023-06, Vol.330, p.227-238</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-f6ac068f7421861442a16a3773e1c11b5085a83d3b630fb632d7303b0d62c3743</citedby><cites>FETCH-LOGICAL-c396t-f6ac068f7421861442a16a3773e1c11b5085a83d3b630fb632d7303b0d62c3743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165032723003245$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36907464$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de A. Simoes Moreira, Debora</creatorcontrib><creatorcontrib>Gauer, Luís Eduardo</creatorcontrib><creatorcontrib>Teixeira, Guilherme</creatorcontrib><creatorcontrib>Fonseca da Silva, Amanda Carolina</creatorcontrib><creatorcontrib>Cavalcanti, Stefanie</creatorcontrib><creatorcontrib>Quevedo, João</creatorcontrib><title>Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis</title><title>Journal of affective disorders</title><addtitle>J Affect Disord</addtitle><description>ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220). We searched MEDLINE, Web of Science, Embase, PsycINFO, Google Scholar, Cochrane Library and trial registries, which were the ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform, without restrictions on publication date. Selection criteria: randomized controlled trials or cohorts comparing ketamine versus ECT in patients with TRD. Eight studies met the inclusion criteria (of 2875 retrieved). Random-effects models comparing ketamine and ECT regarding the following outcomes were conducted: a) reduction of depressive symptoms severity through scales, g = −0.12, p = 0.68; b) response to therapy, RR = 0.89, p = 0.51; c) reported side-effects: dissociative symptoms, RR = 5.41, p = 0.06; nausea, RR = 0.73, p = 0.47; muscle pain, RR = 0.25, p = 0.02; and headache, RR = 0.39, p = 0.08. Influential &amp; subgroup analyses were performed. Methodological issues with high risk of bias in some of the source material, reduced number of eligible studies with high in-between heterogeneity and small sample sizes. Our study showed no evidence to support the superiority of ketamine over ECT for severity of depressive symptoms and response to therapy. Regarding side effects, there was a statistically significant decreased risk of muscle pain in patients treated with ketamine compared to ECT. •To our knowledge, this is the first meta-analysis comparing ketamine and ECT in the treatment of patients with TRD;•Our analysis showed no evidence to support the superiority of ketamine over ECT in reducing depression severity;•There is a lower risk of having muscle pain as a side effect when using ketamine compared with ECT for TRD.</description><subject>Antidepressive Agents - adverse effects</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>ECT</subject><subject>Electroconvulsive Therapy - adverse effects</subject><subject>Humans</subject><subject>Ketamine</subject><subject>Ketamine - adverse effects</subject><subject>MDD</subject><subject>Meta-analysis</subject><subject>Mood disorders</subject><subject>Myalgia - drug therapy</subject><subject>TRD</subject><issn>0165-0327</issn><issn>1573-2517</issn><issn>1573-2517</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUha2Kqp0WHoAN8pJNgn8SOwOrqioUqVI3sLY89rVwSOLBN5kqL8Ez4-kUlmyuF-e758rnEPKWs5ozrj70dW99LZiQNRM1b8UZ2fBWy0q0XL8im8K0FZNCX5IrxJ4xpraaXZBLqbZMN6rZkN93IURn3Urt5Kn1B8gIFEIANyNNgf6E2Y5xAnpUFqQwFCUnl6bDMmA8AJ1_QLb7lYaU6Wj7Mj3sM-Cz6COm7CF_pDcUV5xhtHN0NMMhwtPzzbEcqOxkhxUjvibnwQ4Ib17ea_L989232_vq4fHL19ubh8rJrZqroKxjqgu6EbxTvGmE5cpKrSVwx_muZV1rO-nlTkkWyhBeSyZ3zCvhpG7kNXl_8t3n9GsBnM0Y0cEw2AnSgkboTrWct3xbUH5CXU6IGYLZ5zjavBrOzLEG05tSgznWYJgwpYay8-7FftmN4P9t_M29AJ9OAJRPliiyQRdhcuBjLvkan-J_7P8AJaiaNg</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>de A. Simoes Moreira, Debora</creator><creator>Gauer, Luís Eduardo</creator><creator>Teixeira, Guilherme</creator><creator>Fonseca da Silva, Amanda Carolina</creator><creator>Cavalcanti, Stefanie</creator><creator>Quevedo, João</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20230601</creationdate><title>Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis</title><author>de A. Simoes Moreira, Debora ; Gauer, Luís Eduardo ; Teixeira, Guilherme ; Fonseca da Silva, Amanda Carolina ; Cavalcanti, Stefanie ; Quevedo, João</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-f6ac068f7421861442a16a3773e1c11b5085a83d3b630fb632d7303b0d62c3743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antidepressive Agents - adverse effects</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>ECT</topic><topic>Electroconvulsive Therapy - adverse effects</topic><topic>Humans</topic><topic>Ketamine</topic><topic>Ketamine - adverse effects</topic><topic>MDD</topic><topic>Meta-analysis</topic><topic>Mood disorders</topic><topic>Myalgia - drug therapy</topic><topic>TRD</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de A. Simoes Moreira, Debora</creatorcontrib><creatorcontrib>Gauer, Luís Eduardo</creatorcontrib><creatorcontrib>Teixeira, Guilherme</creatorcontrib><creatorcontrib>Fonseca da Silva, Amanda Carolina</creatorcontrib><creatorcontrib>Cavalcanti, Stefanie</creatorcontrib><creatorcontrib>Quevedo, João</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of affective disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de A. Simoes Moreira, Debora</au><au>Gauer, Luís Eduardo</au><au>Teixeira, Guilherme</au><au>Fonseca da Silva, Amanda Carolina</au><au>Cavalcanti, Stefanie</au><au>Quevedo, João</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis</atitle><jtitle>Journal of affective disorders</jtitle><addtitle>J Affect Disord</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>330</volume><spage>227</spage><epage>238</epage><pages>227-238</pages><issn>0165-0327</issn><issn>1573-2517</issn><eissn>1573-2517</eissn><abstract>ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220). We searched MEDLINE, Web of Science, Embase, PsycINFO, Google Scholar, Cochrane Library and trial registries, which were the ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform, without restrictions on publication date. Selection criteria: randomized controlled trials or cohorts comparing ketamine versus ECT in patients with TRD. Eight studies met the inclusion criteria (of 2875 retrieved). Random-effects models comparing ketamine and ECT regarding the following outcomes were conducted: a) reduction of depressive symptoms severity through scales, g = −0.12, p = 0.68; b) response to therapy, RR = 0.89, p = 0.51; c) reported side-effects: dissociative symptoms, RR = 5.41, p = 0.06; nausea, RR = 0.73, p = 0.47; muscle pain, RR = 0.25, p = 0.02; and headache, RR = 0.39, p = 0.08. Influential &amp; subgroup analyses were performed. Methodological issues with high risk of bias in some of the source material, reduced number of eligible studies with high in-between heterogeneity and small sample sizes. Our study showed no evidence to support the superiority of ketamine over ECT for severity of depressive symptoms and response to therapy. Regarding side effects, there was a statistically significant decreased risk of muscle pain in patients treated with ketamine compared to ECT. •To our knowledge, this is the first meta-analysis comparing ketamine and ECT in the treatment of patients with TRD;•Our analysis showed no evidence to support the superiority of ketamine over ECT in reducing depression severity;•There is a lower risk of having muscle pain as a side effect when using ketamine compared with ECT for TRD.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>36907464</pmid><doi>10.1016/j.jad.2023.02.152</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0165-0327
ispartof Journal of affective disorders, 2023-06, Vol.330, p.227-238
issn 0165-0327
1573-2517
1573-2517
language eng
recordid cdi_proquest_miscellaneous_2786511519
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Antidepressive Agents - adverse effects
Depressive Disorder, Major - drug therapy
ECT
Electroconvulsive Therapy - adverse effects
Humans
Ketamine
Ketamine - adverse effects
MDD
Meta-analysis
Mood disorders
Myalgia - drug therapy
TRD
title Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A06%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20adverse%20effects%20of%20ketamine%20versus%20electroconvulsive%20therapy%20for%20major%20depressive%20disorder:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Journal%20of%20affective%20disorders&rft.au=de%20A.%20Simoes%20Moreira,%20Debora&rft.date=2023-06-01&rft.volume=330&rft.spage=227&rft.epage=238&rft.pages=227-238&rft.issn=0165-0327&rft.eissn=1573-2517&rft_id=info:doi/10.1016/j.jad.2023.02.152&rft_dat=%3Cproquest_cross%3E2786511519%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2786511519&rft_id=info:pmid/36907464&rft_els_id=S0165032723003245&rfr_iscdi=true